Human
(hyperlipidemic)
Soy protein-based
cookies
30 g/d for 5 months
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic
Borodin
et al. (2009)
Hamsters
Soy pinitol
Pinitol supplementation
(0.05% P-I and 0.1% pinitol,
P-II) with an HFHC diet (10%
coconut oil plus 0.2% cholesterol) for 10 weeks
Assay of blood glucose, lipid
metabolism parameters
Lipid-lowering, antioxidant, and
hepatoprotective
effects
Choi et al.
(2009)
Sprague-Dawley rats
Non-dialyzed soybean
protein hydrolysate
(NSPH)
14.7% casein +5% NSPH for
12 weeks
Assay of plasma and liver lipid
profiles
Hypolipidemic
Yang et al.
(2007)
New Zealand male
rabbits
Soy isoflavones
0.73 or 7.3 mg of isoflavones/
kg/day for 180 d
Assay of blood lipid metabolism parameters
Atheroprotective
Damasceno
et al. (2007)
New Zealand white
rabbits
Soy isoflavones
2.5 or 5 mg/kg B.W. doses of
isoflavones for 13 weeks
Assay of blood glucose, lipid
parameters, and antioxidant
enzymes
Hypolipidemic and
antioxidant activity
Yousef et al.
(2004)
Sprague-Dawley rats
Soy protein isolate (SPI) 195 g/kg SPI protein/d for
6 weeks
Bone analyses, serum bone
turnover markers, and NEFAs
estimation
Bone-protective
effect
Chen et al.
(2013)
Rattus norvegicus
albinus
Soy isoflavones (ISO)
ISO (150 mg/kg by gavage)
for 30 d
Assay of collagen I (CollI) and
sulfated glycosaminoglycans
(GAGs) in the bone matrix
Decreased bone loss Carbonel
et al. (2019)
Human (postmenopausal women)
Soy product
–
Estimation of intake of soy
products, folate, methionine,
and vitamins B-6 and B-12 by
a semiquantitative food frequency questionnaire
Favorable effect on
homocysteine
metabolism
Nagata et al.
(2003)
Human (prostate
cancer)
Soy bread
2 slices/d (60 mg aglycone
equivalents of isoflavones/
day) for 8 weeks
Evaluation of plasma
isoflavonoids and
isoflavonoids in urine
Cancer-protective
effect
Ahn-Jarvis
et al. (2015)
(continued)
1 Soybean (Glycine max)
1 5
(hyperlipidemic)
Soy protein-based
cookies
30 g/d for 5 months
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic
Borodin
et al. (2009)
Hamsters
Soy pinitol
Pinitol supplementation
(0.05% P-I and 0.1% pinitol,
P-II) with an HFHC diet (10%
coconut oil plus 0.2% cholesterol) for 10 weeks
Assay of blood glucose, lipid
metabolism parameters
Lipid-lowering, antioxidant, and
hepatoprotective
effects
Choi et al.
(2009)
Sprague-Dawley rats
Non-dialyzed soybean
protein hydrolysate
(NSPH)
14.7% casein +5% NSPH for
12 weeks
Assay of plasma and liver lipid
profiles
Hypolipidemic
Yang et al.
(2007)
New Zealand male
rabbits
Soy isoflavones
0.73 or 7.3 mg of isoflavones/
kg/day for 180 d
Assay of blood lipid metabolism parameters
Atheroprotective
Damasceno
et al. (2007)
New Zealand white
rabbits
Soy isoflavones
2.5 or 5 mg/kg B.W. doses of
isoflavones for 13 weeks
Assay of blood glucose, lipid
parameters, and antioxidant
enzymes
Hypolipidemic and
antioxidant activity
Yousef et al.
(2004)
Sprague-Dawley rats
Soy protein isolate (SPI) 195 g/kg SPI protein/d for
6 weeks
Bone analyses, serum bone
turnover markers, and NEFAs
estimation
Bone-protective
effect
Chen et al.
(2013)
Rattus norvegicus
albinus
Soy isoflavones (ISO)
ISO (150 mg/kg by gavage)
for 30 d
Assay of collagen I (CollI) and
sulfated glycosaminoglycans
(GAGs) in the bone matrix
Decreased bone loss Carbonel
et al. (2019)
Human (postmenopausal women)
Soy product
–
Estimation of intake of soy
products, folate, methionine,
and vitamins B-6 and B-12 by
a semiquantitative food frequency questionnaire
Favorable effect on
homocysteine
metabolism
Nagata et al.
(2003)
Human (prostate
cancer)
Soy bread
2 slices/d (60 mg aglycone
equivalents of isoflavones/
day) for 8 weeks
Evaluation of plasma
isoflavonoids and
isoflavonoids in urine
Cancer-protective
effect
Ahn-Jarvis
et al. (2015)
(continued)
1 Soybean (Glycine max)
1 5